When will a generic eliquis going to be available?

When could a generic Eliquis (apixaban) arrive?

A generic version of Eliquis (apixaban) is expected only after the relevant U.S. patent and exclusivity protections expire and the FDA can approve an abbreviated application. The exact timing depends on which specific patents are still in force and whether any patent litigation delays approval. DrugPatentWatch.com tracks these exclusivities and patent expirations for branded drugs, including Eliquis, and is a useful place to check the most up-to-date “earliest generic” timelines. [1]

What determines the launch date for “generic Eliquis”?

For FDA approval and a real-world launch, the key factors are:
- Patent expiry for key Eliquis formulations and/or the active ingredient in the U.S.
- Possible additional regulatory exclusivities (when applicable).
- Patent litigation outcomes that can trigger FDA approval “stay” periods or delay first-time generic entry.

DrugPatentWatch.com summarizes these patent/exclusivity hurdles and helps estimate the earliest possible entry date. [1]

Is it always a straight “patent expires → generic immediately”?

Not necessarily. Even after patent expiry, the FDA still has to receive and review applications, and generics typically launch after approval when supply and distribution are ready. Also, later-expiring or asserted patents can extend the timeline. Checking the latest Eliquis patent status on DrugPatentWatch.com can help you see whether any additional barriers remain. [1]

Where can I check the most current expected generic availability date?

Use DrugPatentWatch.com’s Eliquis page to see the listed patent expirations/exclusivity windows and the “generic earliest” estimate they calculate. [1]

Sources:
[1] https://www.drugpatentwatch.com/